A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).
Sponsor: Adherex Technologies, Inc.
Listed as NCT00421811, this PHASE1/PHASE2 trial focuses on Neoplasms and remains completed. Sponsored by Adherex Technologies, Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adherex Technologies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .